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Much of the contrast in conventional MRI arises from differences in the NMR relaxation times, especially the spin-lattice 
relaxation time, T1. It is also well known that the variation of T1 with the strength of the magnetic field (known as T1-
dispersion) is tissue-dependent, and that a tissue’s T1-dispersion curve is altered in disease. However, T1-dispersion is 
invisible to conventional MRI scanners, because each scanner can only operate at its own magnetic field (e.g. 1.5 T or 
3.0 T). Our work exploits T1-dispersion as a novel MRI contrast mechanism, by building new types of scanner which 
make use of Fast Field-Cycling (FFC)1.
In FFC, the applied magnetic field B0 is switched rapidly, while the sample (or patient) is inside the scanner. This field 
switching, or cycling, allows the measurement of T1-dispersion. After polarisation (usually at the device’s highest field) 
the field is switched to an intermediate “evolution” field at which relaxation occurs. The magnetic field is finally switched 
back to a high value for signal detection, always at the same field so that the instrument’s radiofrequency system does 
not require retuning during the procedure. 
We have built a range of FFC-MRI equipment, including two whole-body human sized scanners, operating at detection 
fields of 0.06 T and 0.2 T. 2,3 The 0.06 T scanner uses a double magnet, with field-cycling being accomplished by 
switching on and off a resistive magnet inside the bore of a permanent magnet. Our newest scanner (0.2 T) uses a single 
resistive magnet, giving increased flexibility at the expense of greater complexity and increased susceptibility to 
magnetic field fluctuations. Three orthogonal pairs of coils in rectangular Helmholtz configuration provide compensation 
of the Earth’s magnetic field, allowing measurements as low as 1 µT evolution field. A photograph of the scanner is 
shown in Figure 1, while Figure 2 shows typical FFC-MRI images from the scanner.
We are exploring bio-medical applications of FFC-MRI, and early results have shown promise in the areas of thrombosis4
and osteoarthritis5. Recent work on FFC-MRI methodology has focussed on speeding up the collection of FFC-MRI 
images by incorporating rapid MRI scanning methods6 as well as improved pulse sequences and data analysis 
algorithms7.
FFC-MRI is showing significant potential as a new variant of MRI. Our web site (www.ffc-mri.org) contains further 
information, including copies of publications.
Fig. 1 Photograph of the 0.2 T human-scale FFC-MRI scanner. The 
magnet and Earth’s field correction coils can be seen.
Fig. 2 Left: head of normal volunteer at 0.1 T evolution field (FOV 280 
mm; SL 8 mm; 128x128; NEX 1). Right: Array phantom (MnCl2 solns) at 
1 µT evolution field (FOV 300 mm; SL 10 mm; 64x64; NEX 1).
1Lurie D.J., Aime S., et al., Comptes Rendus Physique 11, 136-148 (2010).
2Lurie D.J., Foster M.A., Yeung D. and Hutchison J.M.S., Phys.Med.Biol. 43, 1877-1886 (1998).
3Ross P.J., Broche L.M., Davies G.R. and Lurie D.J., Proc. Intl. Soc. Mag. Reson. Med. 25, 2677 (2017).
4Broche L.M., Ismail S., Booth N.A. and Lurie D.J., Magn.Reson.Med., 67, 1453–1457 (2012).
5Broche L.M., Ashcroft G.P and Lurie D.J., Magn.Reson.Med. 68, 358-362 (2012).
6Ross, P.J., Broche, L.M., and Lurie, D.J., Magn. Reson. Med., 73, 1120-1124 (2015).
7Broche, L.M., Ross, P.J., Pine, K.J., and Lurie, D.J., J. Magn. Reson., 238, 44-51 (2014).
Fast Field-Cycling Magnetic Resonance Imaging 
David J. Lurie, University of Aberdeen 
In Vivo Metabolism of Hyperpolarized Pyruvate in Human
Brain Tumor Patients
Daniele Mammoli1, Ilwoo Park1, Peder EZ Larson1, Jeremy Gordon1, Lucas Carvajal1, Hsin-Yu Chen1,
Mark VanCriekinge1, Robert Bok1, Jason C Crane1, Adam Elkhaled1, James B. Slater1, Marcus Ferrone3, John
Kurhanewicz1, Susan Chang2, Sarah J. Nelson1,4, Daniel B. Vigneron1,4.
1Department of Radiology and Biomedical Imaging, 2Department of Neurological Surgery, 3Department of Clinical Pharmacy,
4Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, United States.
Dissolution Dynamic Nuclear Polarization (d-DNP)[1] is a powerful technique capable of enhancing 1H nuclear polarization by up to 5
orders of magnitude. The clinical potential of d-DNP has been investigated and benefits from several favorable features: ample specificity
(many molecules  can be hyperpolarized),  bio-compatibility  (the hyperpolarized markers  are  neither  radioactive nor  toxic)  and high
sensitivity (signals are several orders of magnitude more intense than the background). The main detriment is that the hyperpolarized
signals fade rapidly with a time constant T1, due to the longitudinal relaxation. Pyruvate is probably the most intensively studied molecule
for d-DNP in vivo applications because of long T1(13C) in both C1 and C2 sites (about 40-60 s in vivo) and of its biological relevance. 
In  literature,  successful  translation  to  a  clinical  trial  of  [1,13C]-pyruvate  was  demonstrated  for  prostate  cancer  patients[2].
Combined injections of [1,13C]- and [2,13C]-pyruvate in rat-brain made it possible to estimate the activity of LDH and PDH in vivo, by
tracking the signals of the downstream reactions and by assuming accurate and compartmentalized models[3]. Furthermore,  13C  in vivo
signals of [1,13C]- pyruvate and lactate were acquired in the brain of primates[4].
As yet, applications of d-DNP in brain patients have not been reported. 
We  present  here  preliminary  results  of  the  detection  of  hyperpolarized
pyruvate in the human brain of 10 glioma patients.  Experiments were carried on
a  3  T  MRI  scanner  using  an  8-channel  13C  RF  coil  for  detection.
A  GE  SpinLab[5] d-DNP  polarizer  was  used  to  hyperpolarize  the  signal  of
[1,13C]-pyruvate. The acquisition scheme consisted of two dynamic sequences:
2D-EPSI, Echo-Planar Spectroscopic Imaging (2 cm thick axial slice, TR = 0.13
s, TE = 6.1 ms, 3 s temporal resolution, variable spatial resolution, see figure 1)
or SLAB slice-localized (3 cm thick axial slice, TR = 3 s, TE = 35 ms, 3 s
temporal resolution, see figure 2). Signals of pyruvate, lactate and bicarbonate
were detected and resolved in frequency, demonstrating excellent SNR. 
Attempts to model the temporal trend of the three resonances provided fair results
for SLAB-acquired data where the SNR is sufficiently high to distinguish signals from
the background. In figure 2, build-up was modeled with a gamma function (simulating
physical arrival of molecules in the region of interest) and conversion from pyruvate to
lactate  or  to  bicarbonate;  decay  with a  single  T1 time  constant  for  all  metabolites.
Preliminary results yield an estimate of the kinetic rates for conversion of pyruvate into
lactate (kPL ~ 0.03 s-1) and into bicarbonate (kPB ~ 0.01 s-1). In case of 2D-EPSI, the
higher spatial resolution resulted in reduced bicarbonate SNR, making it challenging to
model  the  kinetics:  further  improvements  are  needed  to  provide  quantitative  and
spatially-resolved rates. The efficiency of EPI-based detection approaches and the implementation of a 32-channels coil are currently
under evaluation. Larger-scale clinical trials are planned in the future. 
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Fig 1. Left: T2-weighted fast spin echo image.  Right: Sum of spectra
over all time points, acquired with a 2D dynamic EPSI sequence. 
Fig  2. Preliminary  modeling  of  the  temporal  trend  of
pyruvate,  lactate  and  bicarbonate  signals  acquired  with
SLAB dynamic sequence (see text for details).
